Operating CF
$712.90M
Capex
−$71.56M
Free Cash Flow
$641.34M
FCF Margin
+90.0%
Cash flow waterfall for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
Free cash flow: $641.34M
Note: Other Investing is large — driven mainly by purchases or sales of investments.
Cash flow breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $712.90M | $712.90M |
| Capital Expenditure | −$71.56M | $641.34M |
| Free Cash Flow | $641.34M | $641.34M |
| Other Investing | $368.58M | $1.01B |
| Net Debt Change | −$552.65M | $457.26M |
| Other Financing | $219.09M | $676.36M |
| Forex Effect | $13.81M | $690.17M |
| Net Cash Increase | $690.17M | $690.17M |
- Operating Cash Flow$712.90M
- Capital Expenditure−$71.56M
- Free Cash Flow$641.34M
- Other Investing$368.58M
- Net Debt Change−$552.65M
- Other Financing$219.09M
- Forex Effect$13.81M
- Net Cash Increase$690.17M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement